{
    "clinical_study": {
        "@rank": "153158", 
        "acronym": "TGEN", 
        "biospec_descr": {
            "textblock": "Surgery is done and a \"core\" specimen (from the enhancing component of tumor) and one or\n      more tissue biopsies of the surrounding \"rim\" are obtained and processed for shipment to\n      TGen for NGS and transcriptome profiling.\n\n      Blood is obtained prior to and 24 hours following surgery for assessment of any circulating\n      tumor DNA in blood.\n\n      Blood for circulating tumor DNA is collected every 28 days (+/- 7 days)."
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "This current study will use a new treatment approach based on each patient's tumor genomic\n      profiling consisting of whole genome sequencing, exome analysis, and RNA sequencing as well\n      as predictive modeling. This new treatment strategy has shown promising results in adult\n      patients with other solid tumors.\n\n      The current study will test the feasibility of a specialized Tumor Board assigning a\n      treatment plan within 35 calendar days of obtaining tumor tissue. The treatment plan will\n      take into consideration each patient's tumor molecular profile and predictive modeling as\n      well as prior history and treatment(s), and other medical conditions of the patient."
        }, 
        "brief_title": "A Pilot Trial Testing the Feasibility of Molecular Profiling in Recurrent/Progressive Glioblastoma", 
        "condition": [
            "Recurrent Glioblastoma", 
            "Progressive Glioblastoma"
        ], 
        "condition_browse": {
            "mesh_term": "Glioblastoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must understand and provide written informed consent and Health Insurance\n             Portability and Accountability Act (HIPAA) authorization prior to initiation of any\n             study-specific procedures\n\n          -  Have a life expectancy of at least 3 months\n\n          -  Patients must have a diagnosis of histologically confirmed Glioblastoma that is felt\n             on imaging to be progressive despite standard of care treatment\n\n          -  at least 18 years of age\n\n          -  Patient is a good medical candidate for a standard of care surgical procedure\n\n          -  Patients may enroll independent of number of prior therapies, but must have received\n             prior radiation therapy\n\n          -  Patients must have a performance status (KPS) of at least 60.\n\n        Exclusion Criteria:\n\n          -  Uncontrolled concurrent illness including psychiatric illness, or situations that\n             would limit compliance with the study requirements or the ability to willingly give\n             written informed consent\n\n        Eligibility for treatment using the specialized Tumor Board recommendations\n\n          -  Patients must have fully recovered from any toxicity associated with surgery\n\n          -  Must begin treatment no longer than 35 calendar days from surgery\n\n          -  Must have KPS at least 60\n\n          -  Must have Absolute Neutrophil Count (ANC) at least 1500/mm3, platelets at least\n             125,000/mm2, Hg at least 8 gm/dl\n\n          -  Must have electrolytes (Na, K, Co2, Cl) within normal limits using institutional\n             guidelines\n\n          -  Must have baseline MRI within 14 days prior to starting cycle 1, day 1 of treatment\n             (+/- 3 days)\n\n          -  Additional laboratory guidelines will be based upon therapies suggested by the\n             specialized Tumor Board based upon anticipated, known toxicities of those agents and\n             must be within at least 1.5 x upper normal limits of institutional normal limits\n\n          -  Patient must agree to follow the recommended treatment regimen, including clinic\n             visits, laboratory, imaging, and toxicity assessments"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients presenting with recurrent or progressive glioblastoma that are eligible for\n        surgical resection."
            }
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02060890", 
            "org_study_id": "Ivy Precision Trial"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Glioblastoma", 
        "lastchanged_date": "February 11, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Francisco", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94143"
                }, 
                "name": "University of California, San Francisco"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Pilot Trial Testing the Feasibility of Using Molecular Profiling to Guide an Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma", 
        "other_outcome": [
            {
                "description": "Frequency with which unique tumor markers can be detected in the blood circulation and correlation with disease burden and response", 
                "measure": "Tumor Markers vs. Treatment Response", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Genomic fidelity (to the patient's original tumor) in patient-derived xenograft (PDX) models derived from these patients", 
                "measure": "Xenograph genomics", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Efficacy of treatment plan derived from specialized Tumor Board suggestion", 
                "measure": "Efficacy", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "overall_contact": {
            "email": "PradosM@neurosurg.ucsf.edu", 
            "last_name": "Michael Prados, MD", 
            "phone": "415-353-2746"
        }, 
        "overall_contact_backup": {
            "email": "jonathan.aicardi@neurosurg.ucsf.edu", 
            "last_name": "Jonathan Aicardi, CRC", 
            "phone": "415-353-2746"
        }, 
        "overall_official": [
            {
                "affiliation": "University of California, San Francisco", 
                "last_name": "Michael Prados, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of California, San Francisco", 
                "last_name": "Susan Chang, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "University of California, San Francisco", 
                "last_name": "Nicholas Butowski, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "University of California, San Francisco", 
                "last_name": "Jennifer Clarke, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Data and Safety Monitoring Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Feasibility of a specialized Tumor Board making individualized treatment recommendations within 35 calendar days of tumor tissue collection", 
            "measure": "Feasibility", 
            "safety_issue": "Yes", 
            "time_frame": "12 Months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02060890"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of California, San Francisco", 
            "investigator_full_name": "Michael Prados", 
            "investigator_title": "Professor in Residence of Neurological Surgery, Charles B. Wilson MD Endowed Chair", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Treatment plans derived from tumor tissue taken from the \"edge\" of the enhancing disease vs. from the tumor \"core\" from the same patient.", 
            "measure": "Treatment plan comparison", 
            "safety_issue": "No", 
            "time_frame": "35 days"
        }, 
        "source": "University of California, San Francisco", 
        "sponsors": {
            "collaborator": {
                "agency": "Translational Genomics Research Institute, Phoenix, Arizona.", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of California, San Francisco", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}